Ten Minute Interview: Private Market Investments

On April 1, 2026,the U.S. Food & Drug Administration (FDA) issued a statement clarifying its compliance policy on the  conditions that must be met for compounded drugs to qualify for the exemptions under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act).

Foley partner Susan Pravda is a business lawyer focused on mergers and acquisitions, venture capital, initial public offerings, and related securities transactions and is head of Foley’s Health Care & Life Sciences Sector. She also serves as the firm’s chief strategic talent acquisition partner.

Clients faced with defending or initiating litigation often begin with the question: “Can we win?” The question sounds simple enough, and if the law is favorable, the instinctive answer might be “yes.” But “winning” in court doesn’t happen, and can’t be evaluated, in a vacuum. In reality, the odds of success in litigation depend not only on the law and facts of the case but also on any business constraints and potential consequences.